Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.

Nature cardiovascular research·2026
Same author

Structural, biophysical and cellular assessment of filamin C M82K: A test case for VUS interpretation in cardiomyopathy.

Journal of molecular and cellular cardiology·2026
Same author

Re-evaluating evidence for a 'naming bias' in scientific awards.

Nature human behaviour·2026
Same author

A systematic review of explainable artificial intelligence and cardiac electrophysiological models addressing sports-related sudden cardiac death and arrest in adolescents and young adults.

NPJ digital medicine·2026
Same author

A titin truncating variant linked to atrial fibrillation increases atrial profibrotic signalling and cholinergic sensitivity.

Cardiovascular research·2026
Same author

JAK1/2 inhibitor ruxolitinib reduces aggregates in cardiac proteinopathy.

EMBO molecular medicine·2026

Related Experiment Video

Updated: May 27, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

How do MYBPC3 mutations cause hypertrophic cardiomyopathy?

Steven Marston1, O'Neal Copeland, Katja Gehmlich

  • 1NHLI, Imperial College London, London, UK. s.marston@imperial.ac.uk

Journal of Muscle Research and Cell Motility
|November 8, 2011
PubMed
Summary

MYBPC3 mutations, the primary cause of hypertrophic cardiomyopathy (HCM), lead to MyBP-C haploinsufficiency, not a toxic peptide. This haploinsufficiency is the likely mechanism driving HCM development in affected individuals.

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

Related Experiment Videos

Last Updated: May 27, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Genetic Disease Mechanisms

Background:

  • MYBPC3 mutations are the most frequent genetic cause of hypertrophic cardiomyopathy (HCM).
  • HCM mutations in MYBPC3 often occur in introns, predicted to cause aberrant splicing, frameshifts, and premature chain termination.
  • Truncated MYBPC3 peptides are not found in affected human heart tissue.

Purpose of the Study:

  • To investigate the mechanism underlying MyBP-C haploinsufficiency in MYBPC3-related HCM.
  • To explore how MyBP-C haploinsufficiency contributes to the pathogenesis of hypertrophic cardiomyopathy.

Main Methods:

  • Review of existing literature on MYBPC3 mutations and hypertrophic cardiomyopathy.
  • Analysis of molecular mechanisms related to splicing, protein truncation, and haploinsufficiency.
  • Comparison of MYBPC3 mutation effects with other myofibrillar protein mutations in HCM.

Main Results:

  • MYBPC3 mutant human heart muscle consistently exhibits MyBP-C haploinsufficiency.
  • Aberrantly spliced MYBPC3 transcripts do not result in the expression of identifiable truncated peptides.
  • Haploinsufficiency, rather than a 'poison peptide', is the observed consequence of MYBPC3 mutations.

Conclusions:

  • MyBP-C haploinsufficiency is the predominant mechanism by which MYBPC3 mutations cause hypertrophic cardiomyopathy.
  • Understanding this mechanism is crucial for developing targeted therapies for MYBPC3-related HCM.
  • Further research into the precise pathways linking MyBP-C haploinsufficiency to cardiac hypertrophy is warranted.